Literature DB >> 1649244

Differential tissue-specific expression of human apoA-I and apoA-II.

T L Eggerman1, J M Hoeg, M S Meng, A Tombragel, D Bojanovski, H B Brewer.   

Abstract

To evaluate the sources of high density lipoprotein (HDL) particles containing only apolipoprotein A-I (apoA-I), the synthesis of apoA-I and apolipoprotein A-II (apoA-II) was examined in human liver and small intestine as well as the human intestinally derived cell line, Caco-2. Human liver contained apoA-I, apoA-II as well as apolipoprotein B (apoB) mRNA. In contrast, human adult small intestine total and polyA+ RNA had little or no apoA-II despite the presence of apoA-I and apoB. Intestinal biopsies from normal individuals failed to show de novo apoA-II protein synthesis in the media of organ cultures during [35S]methionine pulse-chase labeling, whereas apoA-I could be readily detected. Caco-2 cells contained apoA-II mRNA and secreted apoA-II protein into the tissue culture media. These data indicate that the primary site of human apoA-II synthesis is in the liver and that the small intestine secretes apoA-I-containing high density lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649244

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

Review 2.  Metabolism of high density lipoproteins in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Chang-Ping Wu
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

Review 3.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

4.  FOXO1 and LXRα downregulate the apolipoprotein A-I gene expression during hydrogen peroxide-induced oxidative stress in HepG2 cells.

Authors:  Vladimir S Shavva; Alexandra M Bogomolova; Artemy A Nikitin; Ella B Dizhe; Galina N Oleinikova; Ivan A Lapikov; Dmitry A Tanyanskiy; Andrej P Perevozchikov; Sergey V Orlov
Journal:  Cell Stress Chaperones       Date:  2016-11-28       Impact factor: 3.667

5.  Tumor necrosis factor α stimulates endogenous apolipoprotein A-I expression and secretion by human monocytes and macrophages: role of MAP-kinases, NF-κB, and nuclear receptors PPARα and LXRs.

Authors:  Vladimir S Shavva; Denis A Mogilenko; Ekaterina V Nekrasova; Andrey S Trulioff; Igor V Kudriavtsev; Ekaterina E Larionova; Anna V Babina; Ella B Dizhe; Boris V Missyul; Sergey V Orlov
Journal:  Mol Cell Biochem       Date:  2018-02-13       Impact factor: 3.396

6.  Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

Authors:  D R Booth; S Y Tan; S E Booth; G A Tennent; W L Hutchinson; J J Hsuan; N F Totty; O Truong; A K Soutar; P N Hawkins; M Bruguera; J Caballería; M Solé; J M Campistol; M B Pepys
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

Review 7.  Lipids changes in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Xiao-Ying Zhang; Chang-Ping Wu
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

8.  Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin.

Authors:  Kai Yin; Shi-lin Tang; Xiao-hua Yu; Guang-hui Tu; Rong-fang He; Jin-feng Li; Di Xie; Qing-jun Gui; Yu-chang Fu; Zhi-sheng Jiang; Jian Tu; Chao-ke Tang
Journal:  Acta Pharmacol Sin       Date:  2013-04-08       Impact factor: 6.150

9.  Targeting the Apoa1 locus for liver-directed gene therapy.

Authors:  Marco De Giorgi; Ang Li; Ayrea Hurley; Mercedes Barzi; Alexandria M Doerfler; Nikitha A Cherayil; Harrison E Smith; Jonathan D Brown; Charles Y Lin; Karl-Dimiter Bissig; Gang Bao; William R Lagor
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

10.  Validation of the Antidiabetic and Hypolipidemic Effects of Hawthorn by Assessment of Gluconeogenesis and Lipogenesis Related Genes and AMP-Activated Protein Kinase Phosphorylation.

Authors:  Chun-Ching Shih; Cheng-Hsiu Lin; Yih-Jiun Lin; Jin-Bin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.